BOSTON, MA – March 10, 2010 – Halloran Consulting Group (HCG), a firm that specializes in clinical development strategy and services for established and emerging life sciences companies, today announced the continued expansion of its range of services, with the addition of Claudio Carini, MD, PhD, FRCPath, as a Senior Consultant leading the Biomarker and Translational Medicine efforts.
“Dr. Carini has successfully implemented the inclusion of biomarkers and other translational research into development projects to reduce the length and cost of clinical development, and has managed and coached technical and clinical staff through all phases of clinical development from inception to completion,” said Laurie Halloran, CEO & Managing Partner at HCG.
“Claudio brings a wealth of knowledge and ability to support our clients through all phases of development as well as assist them as they address regulatory hurdles. He has developed several compounds in the anti-inflammatory arena for different indications, and has extensive experience interacting with regulatory agencies,” continued Halloran.
Prior to joining Halloran Consulting, Dr. Carini served as US Head of Clinical Development at FMC, Global Head of Translational Medicine and Head of The Biomarker Allianceä at MDS, Global Head of Biomarkers at Hoffman La Roche, and Therapeutic Area Head of Translational Medicine at Novartis. In these roles, he was responsible for building and leading teams of scientists focused on innovative translational research and for developing strategies for early and late translational studies in support of targets and compounds in the areas of Inflammation and Immunology as well as other therapeutic areas.
Dr. Carini has over 200 publications in national and international peer-reviewed journals, is frequently sought for his expertise at international symposia, and has received several research awards and fellowships. He is also the co-editor of the first textbook on biomarkers, “ Biomarkers in Drug Development: A Handboook of Practice, Application and Strategy,” published in 2010 by John Wiley & Sons. He is a member of various national and international societies and has served on the editorial boards of numerous scientific journals.
Dr. Carini obtained his M.D. from the University of Palermo, Italy. He earned a PhD in Immunology and later an FRCPath from the University of London. He also received specialist diplomas in Respiratory Medicine and in Clinical Immunology at the University of Rome. He has served in different faculty roles at the University College London, University of London, University of Rome “La Sapienza”, Johns Hopkins University and Harvard University.
Halloran Consulting has also added Simona Cipra as Senior Consultant. Simona comes to Halloran with more than 15 years of experience in pharmaceutical and medical device development. Prior to joining Halloran Consulting, Simona held senior leadership roles in clinical operations and program management at Eisai Medical Research, Boston Scientific and The Medicines Company. In those roles, Simona led global teams in a variety of therapeutic areas including oncology, cardiology and women’s health.
About Halloran Consulting Group
Halloran is a life sciences consulting firm specializing in enhancing the development process for biopharmaceutical and medical device companies. Our mission is to empower our clients with practical solutions and expert advice on efficient and effective use of resources, implement appropriate infrastructure that optimizes our clients' development processes while maintaining compliance with regulatory and quality practices, and to promote innovation in the business of life science through thought leadership on best practices and virtual product development.
For more information, visit www.hallorancg.com.
